AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 192.76B +8.9% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.68 |
| Forward PE | 15.32 |
| Dividend | 2.39 (1.90%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 1,263,792 |
| Open | 12,452 |
| Previous Close | 12,428 |
| Day's Range | 12,444 - 12,592 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 15,712.32 (+25.18%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,712p, which is an increase of 25.18% from the latest price.
News
AstraZeneca’s BLA for efzimfotase alfa accepted, granted Priority Review by FDA
Alexion, AstraZeneca’s (AZN) Rare Disease’s Biologics License Application, BLA, for efzimfotase alfa has been accepted and granted Priority Review by the US Food and Drug Administration, FDA, for the ...
AstraZeneca Gains as Enhertu Clears England's Value Gate
AstraZeneca Gains as Enhertu Clears England's Value Gate
AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer
(RTTNews) - AstraZeneca (AZN) and Daiichi Sankyo (4568.T) announced that Enhertu (trastuzumab deruxtecan) has received a positive recommendation from the National Institute for Health and Care Excelle...
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England
AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England's state-run healthcare system, expanding access to a drug that has been ava...
Enhertu Approved by NICE for NHS, Impact on AstraZeneca (AZN) Under Scrutiny
Enhertu Approved by NICE for NHS, Impact on AstraZeneca (AZN) Under Scrutiny
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight
AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg
Berenberg analyst Luisa Hector lowered the firm’s price target on AstraZeneca (AZN) to 150 GBp from 160 GBp and keeps a Buy rating on the shares.
AstraZeneca upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank upgraded AstraZeneca (AZN) to Hold from Sell with a price target of 11,700 GBp, up from 11,500 GBp. The firm cites valuation for the upgrade with the shares…
Why the Market Dipped But Astrazeneca (AZN) Gained Today
In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.
Final Trades: Astrazeneca, Leidos Holdings, Expeditors International and the U.S. 10 year
The Investment Committee give you their top stocks to watch for the second half.
AstraZeneca's ENHERTU and TAGRISSO Show Promise Despite Setbacks
AstraZeneca's ENHERTU and TAGRISSO Show Promise Despite Setbacks
Susan G. Komen® and AstraZeneca Partnership to Make Patient Navigation Available to All
DALLAS--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, has announced a partnership with AstraZeneca to make patient navigation part of the national health care infra...
Olema Oncology price target lowered to $30 from $48 at Stifel
Stifel lowered the firm’s price target on Olema Oncology (OLMA) to $30 from $48 and keeps a Buy rating on the shares after AstraZeneca (AZN) announced on Friday that its…
AZN Looks 11.6% Undervalued on GF Valueâ¢
AZN Looks 11.6% Undervalued on GF Valueâ¢
AZN Looks 11.6% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 11.6% Undervalued on GF Value⢠Amid Strong Dividend Profile
Olema selloff on Astra miss ‘significant overreaction,’ says JPMorgan
JPMorgan analyst Anupam Rama keeps an Overweight rating on Olema Oncology (OLMA) after AstraZeneca (AZN) announced that the SERENA-4 study in patients with ER+/HER2- advanced breast cancer missed stat...
AstraZeneca reports results from DESTINY-Lung04 trial
Results from the DESTINY-Lung04 Phase III trial showed AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu demonstrated a statistically significant and clinically meaningful improvement in progression-free...
AstraZeneca reports updated exploratory results from ADAURA trial
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s (AZN) Tagrisso demonstrated a sustained, clinically meaningful overall survival, or OS, benefit at eight years compared...
AstraZeneca's TAGRISSO Achieves 8-Year Survival Milestone In Early-Stage EGFR- Mutated Lung Cancer
(RTTNews) - AstraZeneca's (AZN) TAGRISSO (osimertinib) delivered an unprecedented eight-year landmark overall survival benefit in early-stage EGFR-mutated non-small cell lung cancer (NSCLC), marking t...
AstraZeneca's Enhertu Improves PFS By 6 Months In First-Line HER2-Mutant NSCLC; Daiichi Stock Up
(RTTNews) - AstraZeneca PLC (AZN) and Daiichi Sankyo Company (4568.T) reported positive results from the Phase 3 DESTINY-Lung04 trial evaluating Enhertu as first-line treatment for patients with unres...
AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the SERENA-4 Phase III trial of Etcamah or camizestrant in combination with palbociclib did not meet the primary endpoint of progression-free ...
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meani...
TAGRISSO (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years com...
Olema selloff on AstraZeneca miss a buying opportunity, says Citi
Citi views the pullback in Olema Oncology (OLMA) after AstraZeneca (AZN) announced the camizestrant plus palbociclib combination did not meet the primary endpoint as a buying opportunity. Astra’s SERE...